RT Journal Article
SR Electronic
T1 Persistence of SARS-CoV-2 immunity, Omicron’s footprints, and projections of epidemic resurgences in South African population cohorts
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.11.22270854
DO 10.1101/2022.02.11.22270854
A1 Sun, Kaiyuan
A1 Tempia, Stefano
A1 Kleynhans, Jackie
A1 von Gottberg, Anne
A1 McMorrow, Meredith L
A1 Wolter, Nicole
A1 Bhiman, Jinal N.
A1 Moyes, Jocelyn
A1 du Plessis, Mignon
A1 Carrim, Maimuna
A1 Buys, Amelia
A1 Martinson, Neil A
A1 Kahn, Kathleen
A1 Tollman, Stephen
A1 Lebina, Limakatso
A1 Wafawanaka, Floidy
A1 du Toit, Jacques
A1 Gómez-Olivé, Francesc Xavier
A1 Mkhencele, Thulisa
A1 Viboud, Cécile
A1 Cohen, Cheryl
A1 the PHIRST group
YR 2022
UL http://medrxiv.org/content/early/2022/02/13/2022.02.11.22270854.abstract
AB Understanding the build-up of immunity with successive SARS-CoV-2 variants and the epidemiological conditions that favor rapidly expanding epidemics will facilitate future pandemic control. High-resolution infection and serology data from longitudinal household cohorts in South Africa reveal high cumulative infection rates and durable cross-protective immunity conferred by prior infection in the pre-Omicron era. Building on the cohort’s history of past exposures to different SARS-CoV-2 variants and vaccination, we use mathematical models to explore the fitness advantage of the Omicron variant and its epidemic trajectory. Modelling suggests the Omicron wave infected a large fraction of the population, leaving a complex landscape of population immunity primed and boosted with antigenically distinct variants. Future SARS-CoV-2 resurgences are likely under a range of scenarios of viral characteristics, population contacts, and residual cross-protection.One Sentence Summary Closely monitored population in South Africa reveal high cumulative infection rates and durable protection by prior infection against pre-Omicron variants. Modelling indicates that a large fraction of the population has been infected with Omicron; yet epidemic resurgences are plausible under a wide range of epidemiologic scenarios.Competing Interest StatementCC has received grant support from Sanofi Pasteur, Advanced Vaccine Initiative, and payment of travel costs from Parexel. AvG has received grant support from Sanofi Pasteur, Pfizer related to pneumococcal vaccine, CDC and the Bill & Melinda Gates Foundation. NW reports grants from Sanofi Pasteur and the Bill & Melinda Gates Foundation. NAM has received a grant to his institution from Pfizer to conduct research in patients with pneumonia and from Roche to collect specimens to assess a novel TB assay. JM has received grant support from Sanofi Pasteur.Clinical TrialNCT02519803Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT02519803 Funding StatementThis work was supported by the National Institute for Communicable Diseases of the National Health Laboratory Service and the U.S. Centers for Disease Control and Prevention [cooperative agreement number: 6 U01IP001048-04-02] and Wellcome Trust (grant number 221003/Z/20/Z) in collaboration with the Foreign, Commonwealth and Development Office, United Kingdom.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The PHIRST-C protocol was approved by the University of Witwatersrand Human Research Ethics Committee (Reference 150808) and the U.S. Centers for Disease Control and Prevention's Institutional Review Board relied on the local review (#6840). The protocol was registered on clinicaltrials.gov on 6 August 2015 and updated on 30 December 2020 (https://clinicaltrials.gov/ct2/show/NCT02519803). Participants receive grocery store vouchers of ZAR50 (USD 3) per visit to compensate for time required for specimen collection and interview.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe investigators welcome enquiries about possible collaborations and requests for access to the data set. Data will be shared after approval of a proposal and with a signed data access agreement. Investigators interested in more details about this study, or in accessing these resources, should contact the principle investigator, Prof Cheryl Cohen, at NICD (cherylc{at}nicd.ac.za).